The landscape of inherited retinal diseases (IRDs) is continuously evolving with new research and clinical trial advancements offering hope to patients and families. Recent updates highlight significant progress in gene therapy, particularly for X-linked Retinitis Pigmentosa (XLRP) and RPE65-associated retinal degeneration (RPE65-RD), underscoring the potential for restoring and preserving vision.

Beacon Therapeutics Reports Positive 12-Month Data for XLRP Gene Therapy

Beacon Therapeutics recently announced encouraging 12-month safety and efficacy results from its Phase 2 DAWN trial of laru-zova (laruparetigene zovaparvovec) for patients with X-linked Retinitis Pigmentosa (XLRP) caused by mutations in the RPGR gene. These findings were presented at the ARVO 2026 Annual Meeting.

Laru-zova, an investigational gene therapy, demonstrated sustained improvements in key measures of visual function. Specifically, data showed promising and sustained enhancements in low luminance visual acuity (LLVA) and mean macular sensitivity as measured by microperimetry. The therapy was generally well-tolerated over the 12-month period, supporting its continued clinical development.

The DAWN trial (NCT06275620) is an ongoing, open-label study evaluating two different dose levels of laru-zova in male participants with XLRP. Notably, 50% of participants receiving the high dose achieved at least a 2-line improvement in LLVA from baseline, with 25% seeing a 3-line improvement. In the low-dose group, 67% of participants experienced at least a 2-line improvement. These results are consistent with earlier 9-month interim readouts.

This positive data from DAWN builds anticipation for the topline results from Beacon's pivotal VISTA trial (NCT04850118), which are expected in the second half of 2026. Laru-zova has received several important regulatory designations, including Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA, highlighting the urgent unmet need for XLRP treatments.

RPE65-RD Gene Therapy Shows Functional Gains Despite Structural Changes

In another significant development, real-world data on voretigene neparvovec (Luxturna), a gene therapy for RPE65-associated retinal degeneration (RPE65-RD), has shown functional benefits for patients, particularly in improving light sensitivity and quality of life. However, a recent study highlighted variable effects on visual acuity and an overall decrease in structural outcomes over 24 months.

Mutations in the RPE65 gene cause early-onset IRDs like Leber congenital amaurosis and certain forms of retinitis pigmentosa, leading to severe night blindness and often legal blindness. Luxturna, approved by the FDA in 2017, delivers a functional RPE65 gene to retinal cells via an AAV2 vector, aiming to restore the visual cycle.

A prospective study conducted in Portugal, involving 12 patients (24 eyes) treated with Luxturna, demonstrated